JULIEN VEYS

About JULIEN VEYS

Julien Veys currently holds a senior leadership position at THX Pharma (formerly Theranexus), where he was appointed Deputy Chief Executive Officer in January 2026 after several years with the company. He also sits within the group’s governance structure and plays a key role in both operational execution and corporate strategy, supporting THX Pharma’s transition toward a more integrated pharmaceutical model focused on regulatory approval, early access, and international commercialization in rare neurology. Before becoming Deputy CEO, he served successively as Chief Business Development Officer and Chief Operating Officer at THX Pharma, having joined the company in January 2016. Company disclosures indicate that he contributed to several major milestones, including Theranexus’ listing on Euronext Growth in 2017, the in-licensing of the Batten-1 program in 2019, and the out-licensing of TX01 to Exeltis in 2024. These achievements point to strong capabilities in business development, deal structuring, and the execution of strategic partnerships. His earlier career was built at Trophos, a biotech company where he worked from 2005 to 2015 in a series of strategic roles, ultimately becoming Chief Business Development Officer. During that period, he contributed to the company’s financing efforts, helped secure funding for R&D, and participated in the process that led to Roche’s acquisition of Trophos. This background gave him a deep understanding of asset valuation, innovation financing, and transaction negotiation in life sciences. Julien Veys holds a science degree from Aix-Marseille University and an MBA from HEC Paris. His profile combines scientific training, commercial acumen, and hands-on experience in biotechnology and pharmaceutical leadership. This makes him particularly well suited to guiding a listed company through clinical development, strategic transitions, and value creation in the rare disease space.